22 May 2013
Keywords: rigel, ra, drug, sees, good, ph, data
Article | 27 February 2006
The USA's Rigel Pharmaceuticals has disclosed strong preliminary data from a Phase I double-blind, placebo-controlled trial to investigate the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 February 2006
© 2013 thepharmaletter.com